skip to content
Detailed Quote
5i Report

Review of WELL Health Technologies

SEP 03, 2021 - We like WELL’s strategy, management, growth trajectory, and sector. The telehealth frenzy last year expanded multiples at a much faster pace than expected. Regardless, WELL trades at a significant discount compared to US peers in telehealth. Rating maintained at ‘B+’

Download Report
Company Profile
Interactive Chart
Key Ratios
Analyst Recommendations
5i Recent Questions

Q: Your Portfolio Analyzer tells me that I need more 'Healthcare" since I only have UNH and Well. Can you suggest an addition?

It also noted that I have zero consumer defensive. Can you suggest two for this sector.

A further note was being over weight in Canada.

Thanks again! Dan

Read Answer Asked by Dan on October 08, 2021

Q: As retirees with moderate risk tolerance, Telus is a 4% core holding in a mainly conservative dividend portfolio. We realize (and like) that Telus Health is a small part of the company. We are considering a 1% position in Well for diversification in Health sector, and would appreciate your thoughts on it. Is this an opportune time to buy, or does 5i expect tax loss selling to put more downward pressure as year-end approaches? Thank you. Edward

Read Answer Asked by Edward on October 07, 2021
Share Information
News and Media